Sort
48,018 grants matching “immunotherapy”
Human mechanisms of virus persistence in an AAV-based mouse model of chronic HBV infection
$491,566Michael D Robek · Albany Medical College · R01 · FY2021 · AI
Personalized Immunotherapy of Patients with Ovarian Cancer
$491,531Paul J Sabbatini · Sloan-Kettering Inst Can Research · P01 · FY2016 · CA
Targeted Inhibition in Leukemia
$491,521Nicolas Nassar · Cincinnati Childrens Hosp Med Ctr · R01 · FY2023 · CA
Targeted Inhibition in Leukemia
$491,521Nicolas Nassar · Cincinnati Childrens Hosp Med Ctr · R01 · FY2022 · CA
Contrast Agents for Far Red and Near Infrared Imaging
$491,492Pti Research, Inc. · R44 · FY2001 · CA
Novel IL-12 Gene Delivery Vehicles for Transformation of Solid Tumors
$491,406Seth M Pollack · Northwestern University At Chicago · R01 · FY2022 · CA
CELLULAR MECHANISMS OF SEPSIS AND ORGAN FAILURE
$491,400Richard Samuel Hotchkiss · Washington University · R01 · FY2012 · GM
Regulation of ER-beta Signaling in Carcinogenesis
$491,400Rong Li · George Washington University · R01 · FY2020 · CA
CELLULAR MECHANISMS OF SEPSIS AND ORGAN FAILURE
$491,399Richard Samuel Hotchkiss · Washington University · R01 · FY2011 · GM
Sunitinib Modulation of Cancer Immunotherapy
$491,332James H Finke · Cleveland Clinic Lerner Com-Cwru · R01 · FY2013 · CA
Catalyzing cancer research through the use of advanced functional genomics and cell engineering technologies
$491,315Molishree Umesh Joshi · University Of Colorado Denver · R50 · FY2025 · CA
Tolerance-programming biomaterial-based Intranasal ASIT for the treatment of autoimmunity
$491,250David Scott Wilson · Johns Hopkins University · DP2 · FY2022 · AI
Tolerance-programming biomaterial-based Intranasal ASIT for the treatment of autoimmunity
$491,250David Scott Wilson · Johns Hopkins University · DP2 · FY2023 · AI
Tolerance-programming biomaterial-based Intranasal ASIT for the treatment of autoimmunity
$491,250David Scott Wilson · Johns Hopkins University · DP2 · FY2021 · AI
Tolerance-programming biomaterial-based Intranasal ASIT for the treatment of autoimmunity
$491,250David Scott Wilson · Johns Hopkins University · DP2 · FY2024 · AI
Tolerance-programming biomaterial-based Intranasal ASIT for the treatment of autoimmunity
$491,250David Scott Wilson · Johns Hopkins University · DP2 · FY2025 · AI
TRANSLATIONAL CLINICAL TRIALS FOR PRIMARY CNS TUMORS
$491,231David Reardon · Duke University · P50 · FY2013 · NS
Renalase inhibition for treatment of unresectable melanoma
$491,209Harriet M Kluger · Yale University · R01 · FY2018 · CA
Lymph node-targeted multistage chemoimmunotherapy for lymphoma
$491,199Susan Napier Thomas · Georgia Institute Of Technology · R01 · FY2022 · CA
Identification of a novel targetable cancer stem cell regulator promoting cancer progression and metastasis in non-small cell lung cancer
$491,137Hui-Kuan Lin · Duke University · R01 · FY2024 · CA
The Adenosinergic Pathway in Tumor-derived Exosomes
$491,088Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · CA
Macrophage-specific nanotherapy for breast cancer
$491,020Bryan Ronain Smith · Michigan State University · R01 · FY2024 · CA
Interplay of inherent promiscuity and specificity in protein biochemical function with applications to drug discovery and exome analysis
$490,958Jeffrey Skolnick · Georgia Institute Of Technology · R35 · FY2023 · GM
Interplay of inherent promiscuity and specificity in protein biochemical function with applications to drug discovery and exome analysis
$490,958Jeffrey Skolnick · Georgia Institute Of Technology · R35 · FY2022 · GM
Interplay of inherent promiscuity and specificity in protein biochemical function with applications to drug discovery and exome analysis
$490,958Jeffrey Skolnick · Georgia Institute Of Technology · R35 · FY2025 · GM